Quarterly ResultMay 11, 2026, 04:16 PM
Catalyst Pharma Q1 Revenue $149.4M; FIRDAPSE & AGAMREE Sales +28%
AI Summary
Catalyst Pharmaceuticals reported strong first quarter 2026 financial results, with total revenues reaching $149.4 million, marking a 5.6% year-over-year increase. Net product revenues from its promoted products, FIRDAPSE and AGAMREE, collectively grew by 28.2% to $135.6 million. The company achieved GAAP net income of $63.7 million and non-GAAP net income of $100.3 million, representing increases of 12.3% and 15.8% respectively. Catalyst ended the quarter with a robust cash position of $755.9 million and no funded debt, benefiting from reduced FIRDAPSE royalty rates.
Key Highlights
- Total Q1 2026 product revenue, net was $149.3 million, a 5.6% year-over-year increase.
- FIRDAPSE and AGAMREE net product revenues totaled $135.6 million, up 28.2% year-over-year.
- FIRDAPSE Q1 2026 net product revenue was $98.9 million, an 18.1% year-over-year increase.
- AGAMREE Q1 2026 net product revenue was $36.7 million, up 66.6% from Q1 2025.
- GAAP net income was $63.7 million ($0.50 diluted EPS), a 12.3% year-over-year increase.
- Non-GAAP net income was $100.3 million ($0.79 diluted EPS), a 15.8% year-over-year increase.
- Cash and cash equivalents were $755.9 million as of March 31, 2026, with no funded debt.
- FYCOMPA Q1 2026 net product revenue decreased 61.3% to $13.8 million following loss of exclusivity.